|
|
Vaccine Detail
|
GM.CD40L Cell Vaccine |
| Vaccine Information |
- Vaccine Name: GM.CD40L Cell Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Type: whole cell cancer vaccine
- Status: Clinical trial
- Host Species for Licensed Use: None
- Antigen: CD40 (NCT00101101; NCT00840931; NCT00101166; NCIT_C48391)
- Immunization Route: Intradermal injection (i.d.)
- Description: This is a cell-based vaccine composed of irradiated tumor cells transduced with granulocyte-macrophage colony-stimulating factor (GM-CSF) and CD40-ligand (CD40L) genes. The vaccine may stimulate an anti-tumoral dendritic cell-mediated host immune response. (NCIT_C48391) Universal GM-CSF-producing and CD40L-expressing bystander cell line is used to form an autologous tumor cell-based vaccine for patients with mantle cell lymphoma in order to make the body build an effective immune response to kill cancer cells. It can be used in combination with Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Dexamethasone, and IL-2. (NCT00101101) The vaccine can be done with bystander and autologous tumor cells for patients with malignant melanoma. (NCT00101166) It can also be combined with lenalidomide for patients with myelodysplastic syndrome (MDS). (NCT00840931)
|
| Host Response |
|
|
| References |
NCIT_C48391: GM.CD40L Cell Vaccine [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C48391]
NCT00101101: Universal Granulocyte Macrophage-colony Stimulating Factor (GM-CSF)-Producing and GM.CD40L for Autologous Tumor Vaccine in Mantle Cell Lymphoma [https://clinicaltrials.gov/study/NCT00101101]
NCT00101166: Universal Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)-Producing and CD40L Expressing Bystander Cell Line for Tumor Vaccine in Melanoma [https://clinicaltrials.gov/study/NCT00101166]
NCT00840931: Immunotherapy Using Lenalidomide + Bystander Vaccine in High Risk Myelodysplastic Syndrome (MDS) [https://clinicaltrials.gov/study/NCT00840931]
|
|
